81 results about "Acute lymphoblastic leukemias" patented technology

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

The present invention discloses a chimeric antigen receptor, a gene and a recombinant expression vector thereof, an engineered CD19 targeting NKT cell and applications thereof. The chimeric antigen receptor is CD19ScFv-CD8-CD137-CD3 zeta, and consists of a hinge region and a transmembrane region of the CD19ScFv and CD8, an intracellular signal structural domain of CD137, and an intracellular signal structural domain of CD3 zeta, and the the hinge region, the transmembrane region, the intracellular signal structural domain of CD137 and the intracellular signal structural domain of CD3 zeta are connected in series. When used to treat advanced stage CD19-positive B-cell acute lymphocytic leukemia, the NKT cell modified by the chimeric antigen receptor CD19ScFv-CD8-CD137-CD3 zeta provided by the present invention has good specific killing activity on leukemic cells, and has certain therapeutic effect on advanced stage CD19-positive B-cell acute lymphocytic leukemia patients who are repeatedly subjected to therapy such as radiotherapy, chemotherapy and symptomatic therapy by other drugs but cannot recover obviously.

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on or associated with pi 105 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

The invention belongs to the field of microbial animal cell lines, and relates to a new human acute B lymphocytic leukemia cell strain CHH-1. The in vitro isolate of the mononuclear cell of the marrow of a patient with firstly-diagnosed acute B lymphocytic leukemia undergoes cell primary culture to obtain the highly aggressive human acute B lymphocytic leukemia cell strain with add(11)(q23) chromosome abnormality, the preservation number of the cell strain is CGMCC No.11797, and the highly aggressive human acute B lymphocytic leukemia cell strain with add(11)(q23) chromosome abnormality is named as human acute B lymphocytic leukemia cell strain CHH-1, has a same clone source with patient's leukemia cells, can be infinitely and stably passed in vitro, and has the characteristics of clonality add(11)(q23) genetic abnormality, high tumorigenicity and high aggressiveness. The new human acute B lymphocytic leukemia cell strain CHH-1 provides a new good cell model for researches of human acute lymphocytic leukemia with No.11 chromosome long arm structure abnormality and development of biomedicines, and has wide prospect and great practical values in revelation of the pathogenesis of the human acute lymphocytic leukemia and development of medicines.

The invention discloses an acute B-lymphocyte leukemia initiated cell phenetic classification kit. The kit is used in cooperation with a sever-color flow cytometer. The structure of the kit is configured with the following fluorescently-labeled monoclonal antibody: CD58FITC, CD10PE, CD34PerCP, CD38APC, CD19APC-Cy7 and CD45PacificBlue. The kit disclosed by the invention can be used for fast and accurately detecting the immunophenotype of the leukemia initiated cell of a B-ALL patient in first visit; and the CD58 expression proportion on the leukemia initiated cell tested by the kit provided by the invention can be used as one of the prognostic indicators of the B-ALL patient, and the indicator has important guiding significance in the prognosis of the B-ALL patient and the decision of a clinic treatment scheme.

The invention discloses a method for constructing humanized Ph chromosome positive acute lymphocytic leukemia mouse model, and the method comprises the following steps: acquisition of leukemia cells, pretreatment of NOD / SCID mouse and implantation of leukemia cells, and implantation of leukemia cells. Specifically, the method comprises: 60Co irradiation of sub-lethal dose combined with a pretreatment with rat anti-mouse CD122 monoclonal antibody, and injection of Ph+ALL bone marrow mononuclear cells from knee joint marrow cavity of NOD / SCID mouse, thereby a humanized Ph+ALL mouse model is established with high molding efficiency and good repeatability; cell sorting is not needed, and the molding process is easy to be operated; the method provides an experiment platform for carrying out mankind Ph+ALL research on the level of living animals, and will promote deep research of domestic Ph+ALL.

The present invention relates to methods for predicting the outcome of therapeutic intervention in cases of leukemia, especially acute lymphoblastic leukemia in children and adults. The present invention evaluates a gene expression profile and identifies prognostic genes of cancers, in particular leukemia, more particularly B-precursor acute lymphoblastic leukemia (ALL). The present invention provides a method of determining prognosis of leukemia, in particular, acute lymphoblastic leukemia, more particularly B-precursor ALL and predicting therapeutic outcome of a patient. The method comprises the steps of first establishing the threshold value of at least three prognostic genes of leukemia, preferably at least eight prognostic genes, or preferably, as many as 26 prognostic genes. Then, the amount of the prognostic gene(s) from a leukemia patient is determined. The amount of the prognostic gene present in that patient is compared with the established threshold value of the prognostic gene(s) which is indicative of therapeutic success or failure, whereby the prognostic outcome of the patient is determined / predicted.

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with pi 105 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelodysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

The invention relates to the technical field of medical detection, in particular to a detection kit for minute residues of B-cell acute lymphocyte leukemia. The detection kit comprises anti CD10, CD19, CD20, CD34, CD38 and CD45 antibodies labeled by different fluoresceins. The detection kit comprises six monoclonal antibody combinations of leukocyte differentiation antigen, and a fluorescence labeling and flow cytometric detection technology is combined to realize that one-time flow cytometric detection can quickly and accurately identify the level and typing of abnormal cells of the minute residues of the B-cell acute lymphocyte leukemia, the obtained detection index can be used as an intermediate result to intuitively judge the prognosis conditions of B-cell acute lymphocyte leukemia patients, and thus important guiding significance is provided for the formulation of clinical treatment schemes for the leukemia patients.

The invention discloses application of CSRP2 serving as a marker for evaluating prognostic risk of adult B-ALL patients. The application provided by the invention is particularly the application of a detection substance for detecting mRNA coding CSRP2 protein in preparation of a product for evaluating the prognostic risk of patients suffering acute b lymphoblastic leukemia or application in evaluation of the prognostic risk of the patients suffering acute b lymphoblastic leukemia. Experimental results prove that CSRP2 low expression may be the independent risk factor of the OS, EFS and RFS of an adult B-ALL patient and may be play important roles in hierarchical diagnosis and prognostic evaluation of B-ALL.

The present invention relates to a method for the treatment, amelioration or elimination of pediatric acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct to a pediatric ALL patient in the need thereof.

The invention relates to tubulin depolymerizing agent polypeptides and application thereof, particularly polypeptides capable of inhibiting polymerization of tubulin and treating acute lymphatic leukemia. The invention is characterized in that the sequence of the tubulin depolymerizing agent polypeptides 1 is CRALERLV disclosed as SEQ NO.1. The invention also relates to application of the tubulin depolymerizing agent polypeptides 1 in preparation of medicines for treating acute lymphatic leukemia. A solid-phase synthesis method is utilized to chemically synthesize the tubulin depolymerizing agent polypeptides 1; and the polypeptides with the bran-new sequence can inhibit tubulin in vitro and treat acute lymphatic leukemia.

The invention discloses a kit for detecting gene mutation of acute lymphoblastic leukemia based on multiplex-PCR targeted high-throughput sequencing and a detection method of the kit. The kit is usedfor detecting multiple exon regions of 19 genes related with the acute lymphoblastic leukemia. The kit contains a primer working solution for detecting relevant gene mutation, a PCR mixed solution, aPCR reaction solution, a digestion solution, a joint P5 and a joint P7. The kit is used for carrying out detection based on a multiplex-PCR targeted high-throughput sequencing technique, has the advantages of high accuracy, sensitivity and throughput and can be used for rapidly and efficiently carrying out standardized quantitative detection on 19 relevant genes of acute lymphoblastic leukemia (ALL).

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

The invention provides a mouse model of acute lymphoblastic leukemia and a modeling method, and relates to the field of biotechnology. The preparation method comprises the following steps: infecting IL-7 stimulated hematopoietic cells with retroviruses with BCR-ABLP190; and transfusing the stimulated hematopoietic cells to syngenic mice. The method has the advantages of being simple and easy to implement in a modeling process and capable of establishing the ph+ALL mouse model in one step. According to the mouse model of the acute lymphoblastic leukemia provided by the invention, the sorted BCR-ABL+B cells are transfused to the syngenic mice for the second time without irradiation treatment, with performance consistent with that of mice of first episode; the model is good in stability; and in addition, the uniformity of recipient mice is enhanced and such risks as accidental death of the recipient mice due to irradiation are reduced.

The invention discloses a group of circRNA markers for diagnosis of childhood ALL and application of the group of the circRNA markers for the diagnosis of childhood ALL. The markers comprise two circRNAs which are has_circ_0117909 as shown in SEQ ID No: 1 and has_circ_0005720 as shown in SEQ ID No: 2. The circRNA biomarkers for diagnosis of childhood ALL provided by the invention can be used forthe diagnosis of the childhood ALL, AUC of the circRNA biomarkers for distinguishing bone marrow of childhood ALL from normal control bone marrow can reach 0.962, the sensitivity reaches 90.9%, and the specificity reaches 95%.

The invention discloses a kit for detecting gene mutations in acute lymphoblastic leukemia based on fluorescence quantitative PCR. The kit comprises a PCR primer pair, a probe, a 2x PCR Nucleotide Mixreaction solution and RNase-Free ddH20. The kit has the advantages that a fluorescence quantitative PCR method is adopted to carry out specific amplification detection on PAX5 and IKZF1 gene mutationregion sequences, while high sensitivity and specificity are ensured, more mutation sites are considered. The detection kit provided by the embodiment is high in sensitivity, good in specificity andsimple to operate, and is a human PAX5 and IKZF1 gene mutation detection kit with excellent performance.

The present invention relates to a method for the treatment, amelioration or elimination of acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct to an adult patient in the need thereof.

The invention relates to the technical field of biomedicine and provides an N-terminal polypeptide of retinoic acid induced protein 16 (RAI16). The N-terminal polypeptide has an amino acid sequence represented by SEQ ID NO: 1 and excellent hydrophylic structures, flexible regions, antigen indexes and surface probability structures. The invention further provides an antibody of the N-terminal polypeptide of the RAI16 and a preparation method of the antibody. The antibody of N-terminal polypeptide of the RAI16, prepared by the invention, is high in valence and good in specificity and can generate a specific conjugation reaction with natural human RAI16 molecules. Furthermore, the invention provides applications of RAI16 N-terminal polypeptide and the antibody thereof in the preparation of vaccines or diagnostic kits for preventing and treating acute lymphoblastic leukemia, lung cancer, liver cancer and the like.

The invention discloses application of a substance for reducing USP1 expression in preparation of a medicine for treating children T-series acute lymphocytic leukemia. The invention discloses short hairpin RNA (Ribonucleic Acid) for forming a stem-loop structure. The short hairpin RNA is shRNA-1 or shRNA-2. The deubiquitination enzyme USP1 has the effects of inhibiting cell apoptosis and promotingcell proliferation in T-series acute lymphocytic leukemia cells, and the invention proves that inhibition of USP1 expression can promote apoptosis of tumor leukemia cells and inhibit proliferation ofleukemia cells. The invention provides a novel way for the treatment of T-series acute lymphocytic leukemia, and the deubiquitinase USP1 is expected to become a potential target for anti-leukemia treatment and has a very wide application prospect in the medical field.

The invention relates to the field of diagnosis kits, and particularly relates to a pair of primer and kit for detecting the specific gene HB-1 of acute B lymphocyte leukemia. The primers for detecting the HB-1 and a probe are an upstream primer sequence as shown in SEQ ID NO:1, a downstream primer sequence as shown in SEQ ID NO:2 and a probe as shown in SEQ ID NO:3; the 5'end of a nucleotide sequence as shown in the SEQ ID NO:3 has a Fam mark, and the 3'end of the nucleotide sequence has a Tamra mark. The kit disclosed by the invention optimizes the probe sequence, simplifies the experimental step, realizes the single step of a detection method, enhances the experimental stability and realizes the quantitative detection of the gene HB-1.

The invention belongs to the field of medicine and molecular detection, in particular to a detection kit for relapse and drug resistance gene mutation of acute lymphoblastic leukemia (ALL) and an application method thereof. The detection kit includes a specific primer for an NT5C2 gene mutation site, which can comprehensively and accurately detect the high mutation site of an NT5C2 gene. The detection result has strong guiding significance for clinical practice, can be used for rapid and accurate detection of relapse and drug resistance of ALL to avoid unnecessary therapeutic drugs and is of great importance in the filed of detection and treatment of ALL. Through mutation detection of the NT5C2 gene related to ALL relapse and drug resistance, the detection kit can better guide the medication and treatment of clinicians, and can be used as an auxiliary means for diagnosis of relapse and drug resistance of the disease.

The invention discloses application of fatsia japonica branch and leaf extractives to anti-cancer drug preparation and preparation of the fatsia japonica branch and leaf extractives, and belongs to the technical field of medicines and natural medicines. A preparation method of the fatsia japonica branch and leaf extractives includes the following steps: ethyl alcohol with 95-percent concentration serves as extracting agents; an ultrasonic extraction method is adopted for extracting fatsia japonica branches and leaves; total ethyl alcohol extractives of the fatsia japonica branch and leaf extractives are obtained; petroleum ether, chloroform and ethyl acetate are sequentially used for extracting the total ethyl alcohol extractives; a petroleum ether part, a chloroform part, an ethyl acetate part and an extraction remaining part are obtained. Meanwhile, supersonic extraction is carried out on the fatsia japonica branches and leaves obtained after extraction with the ethyl alcohol is carried out with distilled water, and an aqueous extract part is obtained. The five extraction parts of the fatsia japonica branches and leaves are of great significance in preparing medicines for treating the breast cancer, the non-small cell lung cancer and the human B-cell acute lymphoblastic leukemia.

The invention relates to succinyl hydrazine compounds derivative and medical compound containing them; and the application of it in preparing medicine that resists leukemia. The succinyl hydrazine compounds derivative shows inhibiting action to BCR-Ab1 tyrosine kinase activity through pharmacological test. It is characterized by high effecivity and low toxicity, and can be widly used to prepare medicine that treats chronic granulocytic leukemia (CML) and philadelphia chromosome positive acute lymphoblastic leukemia, especially medicine treating patient that generates drug resistance to Gleevec.

The embodiment of the invention provides an ALL prognostic related gene mutation detection method, primers and a kit. PCR and sequencing technologies are used, specific primers are mainly used for amplifying specific exon sections of CREBBP genes in genome DNA, sequencing is conducted on target fragments obtained through amplification through a sequencing reaction, and whether mutation exists or not is detected by comparing the obtained sequence with a standard genetic sequence. The detection process is rapid and sensitive, operation is easy, the accuracy is high, and the detection result is definite and clear; the detection specificity is high, a gene mutation detection method which is the most accurate at present is adopted, and purposiveness is high; the blood collection amount of a detection specimen is low, a detected object himself / herself is benefited, fewer experimental instruments are used in the detection process, and the cost is reduced. The invention aims at obtaining analytical data capable of being used for medication guidance and prognosis evaluation of acute lymphoblastic leukemia, and the analytical data can play an important role in the field of medical detection.

The invention discloses a primer probe set, kit and method for quantitative detection of an expression level of a small integral membrane protein 3 (SMIM3) gene. The primer probe set comprises a component A and a component B; the component A includes a forward primer SMIM3-FP, a reverse primer SMIM3-RP and a probe SMIM3-probe; and the component B includes a forward primer ABL1-FP, a reverse primerABL1-RP and a probe ABL1-probe. The primer probe set, the kit and the method have the advantages that quantitative detection of the relative expression level of the SMIM3 gene in a cell is realized;moreover, the sensitivity of the SMIM3 gene and the sensitivity of an ABL1 gene both reach up to 100 copies; the sensitivity is high, results are accurate, and the reliability is high; a new auxiliarydiagnosis method or auxiliary identification method is provided for hematologic tumor cells (especially acute myelogenous leukemia and acute lymphoblastic leukemia); and the primer probe set, the kitand the method have broader application prospects.

The present invention discloses a kit for simultaneously detecting mutations of genes NBPF10, TSFM, PRB2 and DIAPH1, wherein the kit comprises a plurality of multi-gene capture probes, can be used fordetecting the somatic mutations and the germline mutations at the tumor genome level, can be used for the assisted diagnosis of patients with hematological tumors (especially acute lymphoblastic leukemia patients), the monitoring of minimal residual diseases, the evaluation of prognosis, and the like, and can provide important effect in the field of medical detection, wherein the detection methodis simple and sensitive.